{"id":"W2589184568","doi":"10.1111/hae.13191","title":"Pharmacokinetics of a novel extended half‐life glyco<scp>PEG</scp>ylated factor <scp>IX</scp>, nonacog beta pegol (N9‐<scp>GP</scp>) in previously treated patients with haemophilia B: results from two phase 3 clinical trials","year":2017,"lang":"en","type":"article","venue":"Haemophilia","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Novo Nordisk; Baxalta; CSL Behring; LEO Pharma Research Foundation; Biogen Idec; Roche; Bayer; Chugai Pharmaceutical; Pfizer; Alnylam Pharmaceuticals; Boehringer Ingelheim","keywords":"Medicine; Haemophilia; Haemophilia B; Pharmacokinetics; Factor IX; Dosing; Population; Haemophilia A; Half-life; Gastroenterology; Internal medicine; Pediatrics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007959134,0.0004411346,0.0005929642,0.0001295425,0.0001159884,0.0007056194,0.0002532189,0.0004860466,0.0008285827],"category_scores_gemma":[0.0007851016,0.0003241947,0.0006533805,0.0001680798,0.000389884,0.0004696142,0.0001582834,0.001043461,0.0001805938],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005041865,"about_ca_system_score_gemma":0.0004239036,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005863374,"about_ca_topic_score_gemma":0.0008518785,"domain_scores_codex":[0.9997688,0.000106171,0.0000111882,0.00005455881,0.00003033874,0.00002891444],"domain_scores_gemma":[0.999585,0.0001034549,0.0001579567,0.00002660743,0.0000177096,0.0001091559],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4387801,0.01625505,0.06643039,0.00107259,0.003280051,0.0007215053,0.001306037,0.01259229,0.1946104,0.0005352193,0.002940079,0.2614763],"study_design_scores_gemma":[0.1417589,0.6525791,0.1544192,0.0001033779,0.002084612,0.002417773,0.0002073947,0.009911176,0.02874862,0.0003632843,0.007282357,0.0001242479],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980831,0.001279326,0.0002533838,0.00005835106,0.000007157054,0.00005269911,0.0001204201,0.00001152027,0.0001339669],"genre_scores_gemma":[0.9983047,0.0006151202,0.0003571035,0.00008777392,0.00001414449,0.00008512843,0.0002527536,0.000006645687,0.0002766013],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0008285827,"threshold_uncertainty_score":0.00420928,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1451380483141109,"score_gpt":0.431994202506221,"score_spread":0.2868561541921101,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}